- Home
- FUND vs GNLX Comparison
FUND vs GNLX Comparison
Compare FUND & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUND
- GNLX
- Stock Information
- Founded
- FUND 1988
- GNLX 2001
- Country
- FUND Canada
- GNLX United States
- Employees
- FUND N/A
- GNLX N/A
- Industry
- FUND Investment Managers
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- FUND Finance
- GNLX Health Care
- Exchange
- FUND Nasdaq
- GNLX Nasdaq
- Market Cap
- FUND 245.4M
- GNLX 202.4M
- IPO Year
- FUND N/A
- GNLX 2023
- Fundamental
- Price
- FUND $8.20
- GNLX $5.24
- Analyst Decision
- FUND
- GNLX Strong Buy
- Analyst Count
- FUND 0
- GNLX 4
- Target Price
- FUND N/A
- GNLX $19.75
- AVG Volume (30 Days)
- FUND 32.5K
- GNLX 344.1K
- Earning Date
- FUND 01-01-0001
- GNLX 11-05-2025
- Dividend Yield
- FUND 6.64%
- GNLX N/A
- EPS Growth
- FUND N/A
- GNLX N/A
- EPS
- FUND 0.93
- GNLX N/A
- Revenue
- FUND N/A
- GNLX N/A
- Revenue This Year
- FUND N/A
- GNLX N/A
- Revenue Next Year
- FUND N/A
- GNLX N/A
- P/E Ratio
- FUND $8.33
- GNLX N/A
- Revenue Growth
- FUND N/A
- GNLX N/A
- 52 Week Low
- FUND $6.75
- GNLX $1.99
- 52 Week High
- FUND $8.47
- GNLX $8.54
- Technical
- Relative Strength Index (RSI)
- FUND 44.09
- GNLX 40.27
- Support Level
- FUND $8.14
- GNLX $4.34
- Resistance Level
- FUND $8.50
- GNLX $6.26
- Average True Range (ATR)
- FUND 0.12
- GNLX 0.84
- MACD
- FUND -0.00
- GNLX -0.33
- Stochastic Oscillator
- FUND 21.85
- GNLX 21.61
About FUND Sprott Focus Trust Inc.
Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, The Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.